Brokerages Set Xencor, Inc. (NASDAQ:XNCR) Price Target at $24.86

Xencor, Inc. (NASDAQ:XNCR) has received an average recommendation of “Hold” from the nine ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $24.8571.

XNCR has been the topic of a number of research analyst reports. Wall Street Zen upgraded Xencor from a “strong sell” rating to a “hold” rating in a research report on Saturday. JPMorgan Chase & Co. increased their price target on Xencor from $13.00 to $14.00 and gave the stock a “neutral” rating in a report on Monday, May 11th. Zacks Research upgraded shares of Xencor from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Truist Financial decreased their target price on shares of Xencor from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Finally, Cantor Fitzgerald lifted their price target on shares of Xencor from $43.00 to $44.00 and gave the company an “overweight” rating in a research report on Thursday.

Xencor Price Performance

NASDAQ XNCR opened at $20.81 on Friday. The business’s fifty day simple moving average is $15.69 and its 200-day simple moving average is $13.38. The firm has a market cap of $1.55 billion, a PE ratio of -9.59 and a beta of 0.85. Xencor has a 52 week low of $6.92 and a 52 week high of $21.96.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.51. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The firm had revenue of $51.22 million during the quarter, compared to analyst estimates of $18.89 million. During the same quarter in the prior year, the firm posted ($0.41) earnings per share. Xencor’s quarterly revenue was up 17.4% on a year-over-year basis. Research analysts expect that Xencor will post -2.99 EPS for the current year.

Institutional Trading of Xencor

Several institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in Xencor during the 2nd quarter valued at about $219,785,000. Deutsche Bank AG acquired a new stake in shares of Xencor during the second quarter worth about $1,929,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Xencor in the second quarter valued at approximately $352,000. Bank of New York Mellon Corp acquired a new position in shares of Xencor in the second quarter valued at approximately $6,613,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Xencor in the second quarter valued at approximately $556,000.

More Xencor News

Here are the key news stories impacting Xencor this week:

• Positive Sentiment: Quarterly results beat expectations: Xencor reported a second-quarter loss of $0.29 per share, narrower than the $0.80–$0.82 consensus estimate and better than the $0.41 loss recorded a year earlier. Revenue reached approximately $51.2 million, well above the roughly $18.9 million analyst forecast and up 17.4% year over year. Xencor Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Analysts raised valuation expectations: Wedbush increased its price target from $26 to $30 and maintained an “outperform” rating. Cantor Fitzgerald also raised its target from $43 to $44 while keeping an “overweight” rating, signaling substantial potential upside based on their estimates. Analyst Price Target Updates
• Positive Sentiment: RBC Capital reaffirmed its “buy” rating for Xencor, providing additional support for the bullish analyst view following the earnings release. RBC Capital Sticks to Their Buy Rating for Xencor
• Neutral Sentiment: Brokerage consensus remains cautious: Despite several bullish individual ratings, the overall analyst consensus is “hold,” suggesting that expectations for Xencor remain mixed. Xencor Given Consensus Rating of Hold
• Negative Sentiment: Profitability remains a risk: Xencor continues to report net losses, and analysts forecast a full-year loss. The company’s negative margins mean the stock remains dependent on clinical, commercial, and partnership progress to justify its valuation.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.